Details for Patent: 11,865,112

« Back to Dashboard

Which drugs does patent 11,865,112 protect, and when does it expire?

Patent 11,865,112 protects ZURNAI (AUTOINJECTOR) and is included in one NDA.

This patent has seven patent family members in five countries.

Summary for Patent: 11,865,112

Title:	Compositions and methods for opioid antagonist delivery
Abstract:	Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof.
Inventor(s):	Haiyong Hugh Huang, Manjunath S. Shet
Assignee:	Purdue Pharma LP
Application Number:	US16/674,755
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery; Device; Dosage form;

Drugs Protected by US Patent 11,865,112

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Knoa Pharma	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes			Y			TREATING OPIOID OVERDOSE

International Family Members for US Patent 11,865,112

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019376633
Australia	2025267445
Canada	3118708
European Patent Office	3876938